LOUISVILLE, Ky. — Humana still doesn’t know why more people were admitted for short hospital stays than it expected late last year, and that is casting a shadow over health insurers early in 2024.

What You Need To Know

  • Louisville-based Humana reports lower-than-expected earnings forecast

  • Insurers that sell Medicare Advantage plans, such as Humana, continue to struggle with rising care costs

  • Shares of Humana, based in Louisville, Kentucky, shed $50 in midday trading. They sank more than 12% to $352.40 while the Standard & Poor's 500 index rose slightly

Shares of several companies sank again Thursday after Humana debuted an earnings forecast for the new year that fell about $13 short of analyst expectations. Insurer stocks also dropped last week when Humana first disclosed the hospitalization spike and scaled back expectations for 2023.

Health insurers typically see a rise in claims toward the end of each year as flu cases climb and people schedule surgeries before their coverage deductibles renew in January and their out-of-pocket costs rise.

But Humana executives told analysts Thursday that the jump in costs they saw in November and December for Medicare Advantage customers wasn't tied to respiratory illnesses like the flu or COVID-19.

The company saw a rise in patients being admitted to hospitals instead of being held for observation and then released. Chief Financial Officer Susan Diamond said they were still studying claims, but since they don't see signs that the trend was temporary, they had to assume that it will persist through 2024.

The health insurer also is seeing more growth in care that doesn’t involve a hospital stay, like doctor visits and outpatient surgeries and the use of supplemental benefits.

Medicare Advantage plans are privately run versions of the federal government’s Medicare program mostly for people age 65 and older. Humana has nearly 6 million people enrolled in Medicare Advantage plans.

Humana leaders said in a statement Thursday that they believe the rising medical costs were an “industry dynamic” that was not specific to Humana. They also said that the costs “may persist for an extended period or, in some cases, permanently reset the baseline.”

Rival UnitedHealth Group Inc., the only insurer with a bigger Medicare Advantage enrollment, also has struggled with cost hikes and its shares tumbled two weeks ago after saying that its medical costs soared 16%.

But UnitedHealth leaders also have stressed that the rising costs wouldn’t affect their expectations for 2024.

Humana Inc. said Thursday that it expects adjusted earnings of about $16 per share for the new year. Analysts had been projecting per-share earns of $29.14, according to the data firm FactSet.

Jefferies analyst David Windley said he thought Humana's earnings could drop in 2024, maybe to between $20 or $21 per share.

“We did not think $16 was possible,” he said in a research note.

Windley noted that the company appears to be forecasting conservatively by assuming that there will be little moderation in the medical cost trend.

Humana also said Thursday it was backing off a previously announced goal of adjusted earnings of $37 a share for 2025 as it prioritizes improving profitability over enrollment growth.

Shares of Humana, based in Louisville, Kentucky, shed $50 in midday trading. They sank more than 12% to $352.40 while the Standard & Poor's 500 index rose slightly.

UnitedHealth dropped 5%. The Blue Cross-Blue Shield insurer Elevance Health also was down even though it reported on Wednesday a medical cost trend that was better than analysts expected.

Related Stories